theSauceman
3 years ago
Simply a quote: "Anthony Dudzinski, COO, stated, "To date, participants have completed the initial screening process, meeting our extensive inclusion/exclusion criteria, and treatments and follow up assessments have begun. We believe that ATCELL™ for PCS is a ‘first of its kind' autologous cellular therapy protocol subject to FDA clinical studies that has the ability to become an industry standard to treat patients suffering from the effects of post-concussion syndrome resulting from mild traumatic brain (mTBI) injuries. Treatments will become available upon completion of clinical studies and FDA marketing approval.""
https://finance.yahoo.com/news/american-cryostem-announces-patient-treatment-110000832.html
StockLogistics
3 years ago
Parlor trick: as the 20,000,000 “retired shares” bought back from AMCY are only cancelled till November 11,2022 when AMCY can convert its series A shares back into 20,000,000 common shares of CRYO, call it a temporary retirement or shares to dilute this increase to pay for its operations for one year, PR was full of fluff, would take a long time to see progress from whatever it was projecting, they have to pay AMCY 200,000 a quarter for 4 quarters as part of the deal as well, all imo
jobynimble
3 years ago
8-K filing today: https://www.sec.gov/ix?doc=/Archives/edgar/data/1468679/000101905621000598/acryo_8k.htm
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Pursuant to a Share Exchange Agreement, dated as of November 12, 2021, by and between American CryoStem Corporation, a Nevada corporation (the “Company”) and ASC Global, Inc., a Nevada corporation, whose shares of common stock are quoted on the OTC Market Group’s OTC Pink Tier Market under the symbol “AMCY” (“AMCY”), the Company issued to AMCY 1,000,000 shares of its Series A convertible preferred stock (the “A Shares”) in exchange for 20,000,000 shares of common stock, par value $0.001 per share, of the Company held by AMCY, reducing the outstanding shares of the Company’s common stock from 62,057,355 to 42,057,355. Each A Share will be convertible at the option of AMCY into twenty (20) shares of the Company’s common stock commencing on November 11, 2022 and, subject to Nevada law, is entitled to an annual dividend equal to $0.20 per A Share payable quarterly, in cash, or at the option of the Company, in shares of Company common stock with each such share of common stock having a value for such purposes equal to the average VWAP for the five (5) consecutive trading days with the fifth consecutive trading day being the last trading day of the calendar quarter for which such dividend is being paid.
Except as required by Nevada law or otherwise provided in the Company’s Certificate of Designation of Rights, Preferences and Privileges of Series A Convertible Preferred Stock (the “Certificate of Designation”), the A Shares shall vote as common stock on an as-converted basis with the Company’s then outstanding common stock.
The above is a summary only of the rights, preferences and privileges of the A Shares and is qualified in its entirety to the Certificate of Designation attached hereto as Exhibit 3.1.
John Arnone and Anthony Dudzinski, the sole officers and directors of the Company who collectively beneficially own 30,260,000 shares of common stock of the Company, or approximately 45.4% of the outstanding Company common stock are the sole officers and directors of AMCY and collectively beneficially own 48,270,000 shares of common stock of AMCY, or 59.5% of the outstanding AMCY common stock.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. Description
3.1 Certificate of Designation of Rights, Preferences and Privileges of Series A Convertible Preferred Stock.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)